Alterity Therapeutics Limited
Prana Biotechnology is developing first-in-class therapies to treat neurodegenerative disease.
Alterity Therapeutics was incorporated in Melbourne, Australia in 1997 as Prana Biotechnology and has offices in Melbourne, Australia, and San Francisco, USA. The Company listed on the Australian Securities Exchange in 2000 and listed on the NASDAQ in 2002.
The company operates under the ticker codes ASX: ATH and NASDAQ: ATHE
Alterity’s lead candidate, PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. PBT434 has been shown to reduce abnormal accumulation of α-synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain. In this way, it has excellent potential to treat various forms of atypical Parkinsonism.
Parkinsonian disorders are a group of diseases in which individuals experience slowness of movement, stiffness and tremor, a constellation of symptoms referred to as Parkinsonism. Although the most common neurodegenerative cause of these symptoms is Parkinson’s disease there are less common, atypical forms in which patients experience parkinsonism as well as other debilitating symptoms. Neurodegenerative causes of atypical parkinsonism include Multiple System Atrophy, Progressive Supranuclear Palsy, Dementia with Lewy Bodies, among others. The atypical forms of Parkinsonism have additional, associated symptoms and often respond poorly to drugs for treating the motor symptoms of Parkinson’s disease.
The first disease target selected by Alterity Therapeutics is Multiple System Atrophy, a highly debilitating disease with no approved treatments.
ATHE SECURITY DETAILS
Held at DTC